臨床試驗支援服務市場－全球產業規模、佔有率、趨勢、機會及預測（按服務、申辦方、地區及競爭格局分類，2021-2031年）

全球臨床試驗支援服務市場預計將從 2025 年的 217.6 億美元成長到 2031 年的 296.8 億美元，複合年成長率為 5.31%。

這些服務包括專業的行政和營運職能，例如試驗地點選擇、病患招募、資料管理和法規遵從，製藥和生物技術公司將這些職能外包，以確保臨床試驗的有效進行。推動該市場成長要素是試驗通訊協定日益複雜以及縮短藥物研發週期的迫切需求，迫使企業依賴外部專業知識來簡化營運。大量投資支撐著這一需求，歐洲製藥工業協會聯合會 (EFPIA) 報告稱，2023 年歐洲製藥業將在研發方面投資約 524 億歐元。

阻礙市場成長的一大挑戰是招募和留住合格試驗參與者的持續困難。病患流失率高以及接觸不同族群的後勤障礙常常導致成本高昂的延誤和研究週期延長。這些瓶頸造成了嚴重的效率低下，耗費了服務提供者和申辦者的大量資源，有效地限制了整個臨床研究生態系統及時交付結果的能力，並延緩了新療法的推出。

市場促進因素

生物製藥領域研發支出不斷成長是推動市場發展的根本動力。將非核心職能策略性外包給專業供應商對於維持財務永續性至關重要。由於面臨最佳化資本配置和降低臨床試驗失敗相關財務風險的壓力，藥物研發企業越來越依賴外部支援來進行監測、資料管理和監管事務。這一趨勢體現在對開發平臺的大量資本投入上，例如，默克公司在其2023年年度報告中披露，其年度研發支出高達305億美元。這反映了一項強力的投資策略，該策略將持續滿足臨床研究生態系統內對營運專業知識的需求。

同時，慢性病和感染疾病的日益普及擴大了臨床研究的範圍，增加了所需試驗的數量和複雜性。疾病負擔的快速成長迫使申辦方，尤其是在腫瘤學和免疫學領域，啟動需要大規模病患招募、研究中心管理和物流協調的大規模研究。根據美國癌症協會發布的《2024年癌症事實與數據》，預計僅在美國就將新增2,001,140例癌症病例，凸顯了對新型治療方法進行嚴格臨床評估的迫切需求。這種醫療需求也體現在市場活動中，美國食品藥物管理局（FDA）在2023年核准了55種新型療法就證明了這一點。如此高的核准數量凸顯了順利完成監管流程所需的廣泛支援服務的重要性。

市場挑戰

招募和留住合格試驗參與者的持續挑戰，嚴重限制了全球臨床試驗支援服務市場的發展。未能達到患者入組目標會延長整體臨床開發週期，迫使支援服務提供者將人力和技術資源投入到正在進行的計劃中，且持續時間遠超預期。這種積壓導致合約研究組織 (CRO) 和專業供應商無力啟動新契約，直接限制了收入潛力，並減緩了整體市場周轉率。

根據臨床研究專業人員協會 (ACRP) 的預測，到 2024 年，36% 的臨床研究機構將把病患招募和留存視為影響研究結果的最大營運挑戰。由於服務費用通常與特定的入組里程碑掛鉤，這些延誤會擾亂市場的財務生態系統。因此，無法有效率地招募患者限制了產業的規模化發展能力，即使全球對臨床研究的需求不斷成長，也有效地阻礙了支持服務的發展。

市場趨勢

人工智慧 (AI) 在預測分析和病患招募的應用，正從根本上改變臨床試驗的運作方式，實現更精準的試驗中心選擇和資料處理速度的提升。服務供應商正積極部署機器學習演算法，分析電子健康記錄，以比傳統篩檢方法更準確地識別合格的患者群體。這項技術變革直接解決了人工資料處理效率低下的難題，使申辦方能夠最佳化通訊協定可行性並有效縮短試驗週期。根據皮斯托亞聯盟發布的《2025 年未來實驗室全球調查》，63% 的生命科學公司將人工智慧視為關鍵技術投資領域，這標誌著為維持營運競爭力，試驗執行策略正發生決定性轉變，轉向自動化、數據驅動的模式。

分散式和混合式臨床試驗模式的普及代表著服務提供方式的一次重要變革，它將研究活動從實體機構轉移到患者家中，並透過遠端醫療和行動醫療支援來實現。這種模式不僅透過減少患者的出行負擔來提高患者的參與率，而且還成為滿足有關參與者多樣性監管要求的主要途徑。透過消除地域障礙，支持服務可以有效地涵蓋那些通常被排除在傳統機構研究之外的代表性不足的人群。塔夫茨藥物研發研究中心於2025年1月發布的一項PACT聯盟分析發現，分散式試驗方法將亞洲患者的參與率從傳統試驗的14.2%提高到20.9%，這表明該模式在擴大人群覆蓋範圍和提高數據代表性方面具有顯著成效。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球臨床試驗支援服務市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依服務項目分類（臨床試驗中心管理、病患招募管理（病患招募與登記服務、病患保留等）、資料管理、行政人員、倫理審查委員會等）
  • 依贊助商分類（藥品/生物藥品、醫療設備、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美臨床試驗支援服務市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲臨床試驗支援服務市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區臨床試驗支援服務市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲臨床試驗支援服務市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲臨床試驗支援服務市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球臨床試驗支援服務市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Charles River Laboratories International, Inc.
• Wuxi Apptec
• IQVIA Inc
• Syneos Health
• Eurofins Scientific
• Ppd, Inc（Thermo Fisher Scientific Inc.）
• ICON plc
• Laboratory Corporation Of America Holdings
• Parexel International（MA）Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Clinical Trials Support Services Market is projected to expand from USD 21.76 Billion in 2025 to USD 29.68 Billion by 2031, reflecting a CAGR of 5.31%. These services comprise specialized administrative and operational activities-such as site selection, patient recruitment, data management, and regulatory compliance-that pharmaceutical and biotechnology sponsors outsource to ensure the effective execution of clinical studies. The market is primarily driven by the increasing complexity of trial protocols and the urgent need to accelerate drug development timelines, which compels companies to rely on external expertise for operational efficiency. This demand is underpinned by substantial financial commitments, evidenced by the European Federation of Pharmaceutical Industries and Associations reporting that the pharmaceutical industry invested approximately €52.4 billion in research and development across Europe in 2023.

A significant challenge that could hinder market growth is the persistent difficulty in recruiting and retaining eligible trial participants. High patient dropout rates and the logistical hurdles involved in accessing diverse demographic groups frequently result in costly delays and prolonged study durations. These bottlenecks create substantial inefficiencies that strain the resources of both service providers and sponsors, effectively limiting the overall capacity of the clinical research ecosystem to deliver timely results and delaying the introduction of new medical therapies.

Market Driver

Escalating biopharmaceutical R&D expenditures serve as a fundamental catalyst for the market, necessitating the strategic outsourcing of non-core functions to specialized providers to maintain financial viability. As drug developers face increasing pressure to optimize capital allocation and mitigate the financial risks associated with clinical failures, they increasingly rely on external support for monitoring, data management, and regulatory affairs. This trend is demonstrated by massive capital injections into development pipelines; for instance, Merck & Co., Inc. reported full-year R&D expenses of $30.5 billion in their 2023 Annual Report, reflecting an intense investment strategy that sustains the demand for operational expertise within the clinical research ecosystem.

Concurrently, the rising prevalence of chronic and infectious diseases is expanding the scope of clinical research, increasing both the volume and complexity of necessary trials. This surge in disease burden compels sponsors to initiate large-scale studies requiring extensive patient recruitment, site management, and logistical coordination, particularly in oncology and immunology. According to the American Cancer Society's 'Cancer Facts & Figures 2024', it was projected that 2,001,140 new cancer cases would be diagnosed in the United States alone, signaling a critical need for robust clinical evaluation of new treatments. This medical need translates into market activity, as evidenced by the U.S. Food and Drug Administration confirming the approval of 55 novel therapeutics in 2023, a high volume that underscores the extensive support services required to navigate the regulatory pathway.

Market Challenge

The persistent struggle to recruit and retain eligible trial participants constitutes a severe bottleneck for the Global Clinical Trials Support Services Market. When patient enrollment targets are missed, the entire clinical development timeline is extended, forcing support service providers to allocate personnel and technological resources to ongoing projects for periods significantly longer than anticipated. This operational stagnation prevents Contract Research Organizations (CROs) and specialty vendors from freeing up capacity to initiate new contracts, thereby directly capping their revenue potential and slowing overall market turnover.

According to the Association of Clinical Research Professionals, in 2024, 36% of clinical research sites identified recruitment and retention as a top operational challenge impacting their study performance. Such delays disrupt the financial ecosystem of the market, as service payments are frequently tied to specific enrollment milestones. Consequently, the inability to efficiently secure participants creates a drag on the industry's capacity to scale, effectively hampering the growth of support services despite the rising global demand for clinical research.

Market Trends

The integration of Artificial Intelligence (AI) for predictive analytics and patient recruitment is fundamentally reshaping clinical trial operations by enabling more precise site selection and accelerating data processing. Service providers are increasingly deploying machine learning algorithms to mine electronic health records, identifying eligible patient populations with higher accuracy than traditional screening methods. This technological shift directly addresses the inefficiencies of manual data handling, allowing sponsors to optimize protocol feasibility and reduce trial timelines effectively. According to the Pistoia Alliance's 'Lab of the Future 2025 Global Survey', 63% of life science organizations identified AI as their primary technology investment area, signaling a decisive move toward automated, data-driven trial execution strategies to maintain operational competitiveness.

The widespread adoption of decentralized and hybrid clinical trial models represents a critical evolution in service delivery, moving study activities from physical sites to patients' homes via telemedicine and mobile healthcare support. This model not only enhances patient retention by reducing travel burdens but also serves as a primary mechanism for meeting regulatory requirements regarding participant diversity. By dismantling geographical barriers, support services can effectively reach underrepresented demographics that traditional site-based studies often exclude. According to the Tufts Center for the Study of Drug Development's 'PACT Consortium Analysis' in January 2025, decentralized trial methods increased the participation rate of Asian patients to 20.9% compared to just 14.2% in traditional trials, validating the model's efficacy in expanding population access and data representativeness.

Key Market Players

• Charles River Laboratories International, Inc.
• Wuxi Apptec
• IQVIA Inc
• Syneos Health
• Eurofins Scientific
• Ppd, Inc (Thermo Fisher Scientific Inc.)
• ICON plc
• Laboratory Corporation Of America Holdings
• Parexel International (MA) Corporation

Report Scope

In this report, the Global Clinical Trials Support Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trials Support Services Market, By Service

• Clinical Trial Site Management
• Patient Recruitment Management (Patient recruitment & registry services, Patient retention, Others)
• Data Management
• Administrative staff
• IRB
• Others

Clinical Trials Support Services Market, By Sponsor

• Pharmaceutical & Biopharmaceutical
• Medical Devices
• Others

Clinical Trials Support Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trials Support Services Market.

Available Customizations:

Global Clinical Trials Support Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trials Support Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Clinical Trial Site Management, Patient Recruitment Management( Patient recruitment & registry services, Patient retention, Others), Data Management, Administrative staff, IRB, Others)
  • 5.2.2. By Sponsor (Pharmaceutical & Biopharmaceutical, Medical Devices, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Clinical Trials Support Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Sponsor
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Trials Support Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Sponsor
  • 6.3.2. Canada Clinical Trials Support Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Sponsor
  • 6.3.3. Mexico Clinical Trials Support Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Sponsor

7. Europe Clinical Trials Support Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Sponsor
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Trials Support Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Sponsor
  • 7.3.2. France Clinical Trials Support Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Sponsor
  • 7.3.3. United Kingdom Clinical Trials Support Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Sponsor
  • 7.3.4. Italy Clinical Trials Support Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Sponsor
  • 7.3.5. Spain Clinical Trials Support Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Sponsor

8. Asia Pacific Clinical Trials Support Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Sponsor
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Trials Support Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Sponsor
  • 8.3.2. India Clinical Trials Support Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Sponsor
  • 8.3.3. Japan Clinical Trials Support Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Sponsor
  • 8.3.4. South Korea Clinical Trials Support Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Sponsor
  • 8.3.5. Australia Clinical Trials Support Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Sponsor

9. Middle East & Africa Clinical Trials Support Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Sponsor
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Trials Support Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Sponsor
  • 9.3.2. UAE Clinical Trials Support Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Sponsor
  • 9.3.3. South Africa Clinical Trials Support Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Sponsor

10. South America Clinical Trials Support Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Sponsor
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Trials Support Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Sponsor
  • 10.3.2. Colombia Clinical Trials Support Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Sponsor
  • 10.3.3. Argentina Clinical Trials Support Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Sponsor

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Trials Support Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Charles River Laboratories International, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Wuxi Apptec
• 15.3. IQVIA Inc
• 15.4. Syneos Health
• 15.5. Eurofins Scientific
• 15.6. Ppd, Inc (Thermo Fisher Scientific Inc.)
• 15.7. ICON plc
• 15.8. Laboratory Corporation Of America Holdings
• 15.9. Parexel International (MA) Corporation

16. Strategic Recommendations

17. About Us & Disclaimer